Loading
POD Stock: price and insider trades · Australia
No insider purchase over the last 90 days. The latest was filed 14 May 2026.
POD: what insiders have been doing
This page follows insider dealings at POD as filed with ASX, a company from the Healthcare & Pharma sector. The last twelve months, up to 17 October 2026, brought 3 filings signed by 1 insider.
Every open-market trade in the period is a purchase: 2 purchases worth €214k, from 1 insider, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €133k, bought and made public on 21 April 2026 (0.65% of market cap). On the buying side, the filings list 1 senior executive among the declarants.
Compared with its exchange (2,222 companies, median 3 filings), a count of 3 filings is typical. Over the whole record (from 2026), the tally stands at 2 purchases and no sales.
The clock since the last published purchase (14 May 2026) now reads 156 days.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by ASX. They describe what insiders did and are not a recommendation.
Insider Decl.
3
Thresholds
n/a
Buy Volume
€214,250
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleUnknown2 buys
Since the insiders bought
- Unknown-30.6%Entry A$0.05 · Close at T+90 A$0.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,770 of 24,148 companies
29.4
score / 100
Value16
Quality43
FCF yld-11%
Earn yld-8.1%
EV/EBITDA·
ROE-13%
Gross mgn72%
Net mgn-0.1%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2024FY ended June 2024 · cache
A$0.03
Analyst consensus
1 analysts0.00/5
A$0.21Target A$0.21(+600%)A$0.21
Income statement
RevenueA$2.7B
Gross profitA$1.9B72% margin
EBITDA-A$2.3M-0% margin
Net income-A$2.4M0.0% margin
Valuation
PER (trailing)36.9x
PER (forward)-6.0x
P/Book0.8x
Beta1.28
Balance sheet & cash
Market capA$30M
Total debtA$29.1k
Free Cash Flow-A$3.3M
Debt / Equity0%
Profitability & ownership
ROE-13.3%
ROA-8.4%
% insiders31.1%
% institutions1.2%
Last declaration on 6 July 2026
About POD
POD is a company operating in the health and pharmaceutical sector. It is listed on the XASX market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
